肥厚型心肌病的基因型与终身疾病负担:SHaRe注册研究启示
SHaRe国际多中心注册研究纳入4591例肥厚型心肌病患者(2763例完成基因分型),平均随访5.4±6.9年,分析心脏骤停、心脏移植、ICD恰当治疗、全因死亡、房颤、卒中、NYHA III/IV级症状及LVEF<35%等结局。结果显示诊断年龄和肌节突变状态可预测结局,年轻患者及携带致病/可能致病肌节突变者不良结局风险显著更高,心衰和房颤是最常见不良事件但多在诊断后数年出现。
要点
- 诊断年龄和肌节突变状态是肥厚型心肌病不良结局的强预测因素。
- 诊断时<40岁患者至60岁时总体复合结局累积发生率达77%。
- 携带致病/可能致病肌节突变者不良结局风险约为无突变者的两倍。
核心结论
- 肥厚型心肌病的累积疾病负担显著,以诊断后多年出现的心力衰竭和心房颤动为主。
- 年轻诊断年龄和携带肌节突变是不良结局的强预测因素。
研究设计与样本
- Sarcomeric Human Cardiomyopathy Registry(SHaRe)为国际多中心注册研究,汇总八个国际肥厚型心肌病专科中心整理的纵向数据集。
- 共纳入4591例肥厚型心肌病患者,其中2763例完成基因分型,平均随访5.4±6.9年(共24,791患者年;中位随访2.9年,四分位距0.3-7.9年)。
主要发现
- 诊断中位年龄为45.8岁(四分位距30.9-58.1岁),女性占37%。
- 诊断时<40岁患者至60岁时总体复合结局累积发生率为77%(95%CI 72%-80%),而诊断时>60岁患者至70岁时为32%(95%CI 29%-36%)。
- 20-29岁年轻肥厚型心肌病患者死亡率约为同年龄美国一般人群的4倍。
- 携带致病/可能致病肌节突变者不良结局风险约为无突变者的两倍,意义未明肌节变异与中间风险相关。
- 诊断时<40岁患者室性心律失常发生率为32%(95%CI 23%-40%),而>60岁患者为1%(95%CI 1%-2%)。
临床怎么用
- 应将诊断年龄和肌节突变状态纳入肥厚型心肌病患者风险评估,对年轻诊断及携带致病/可能致病突变者加强终身监测。
- 鉴于心衰和房颤多在诊断后数年出现,需长期随访以早期识别并管理这些并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A better understanding of the factors that contribute to heterogeneous outcomes and lifetime disease burden in hypertrophic cardiomyopathy (HCM) is critically needed to improve patient management and outcomes. The Sarcomeric Human Cardiomyopathy Registry (SHaRe) was established to provide the scale of data required to address these issues, aggregating longitudinal datasets curated by eight international HCM specialty centers. METHODS: Data on 4591 HCM patients (2763 genotyped), followed for a mean of 5.4±6.9 years (24,791 patient-years; median [interquartile range] 2.9 [0.3-7.9] years) were analyzed regarding cardiac arrest, cardiac transplantation, appropriate implantable cardioverter-defibrillator (ICD) therapy, all-cause death, atrial fibrillation, stroke, New York Heart Association Functional Class III/IV symptoms (all comprising the overall composite endpoint), and left ventricular ejection fraction (LVEF)<35%. Outcomes were analyzed individually and as composite endpoints. RESULTS: Median age of diagnosis was 45.8 [30.9-58.1] years and 37% of patients were female. Age of diagnosis and sarcomere mutation status were predictive of outcomes. Patients <40 years old at diagnosis had a 77% [95% confidence interval: 72%, 80%] cumulative incidence of the overall composite outcome by age 60, compared to 32% [29%, 36%] by age 70 for patients diagnosed >60 years. Young HCM patients (20-29 years) had 4-fold higher mortality than the general United States population at a similar age. Patients with pathogenic/likely pathogenic sarcomere mutations had two-fold greater risk for adverse outcomes compared to patients without mutations; sarcomere variants of uncertain significance were associated with intermediate risk. Heart failure and atrial fibrillation were the most prevalent adverse events, although typically not emerging for several years after diagnosis. Ventricular arrhythmias occurred in 32% [23%, 40%] of patients <40 years at diagnosis, but in 1% [1%, 2%] >60 years. CONCLUSIONS: The cumulative burden of HCM is substantial and dominated by heart failure and atrial fibrillation occurring many years following diagnosis. Young age of diagnosis and the presence of a sarcomere mutation are powerful predictors of adverse outcomes. These findings highlight the need for close surveillance throughout life, and the need to develop disease-modifying therapies.
引用
- Ho CY, Day SM, Ashley EA, et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018. PMID: 30297972. doi:10.1161/CIRCULATIONAHA.117.033200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。